McKesson Stock Price, News & Analysis

McKesson Corporation (MCK) has announced an increase in its cash tender offer to purchase up to $922,154,000 of its outstanding Notes, up from the initial $500,000,000. This offer includes various series of Notes, with acceptance of all validly tendered and not withdrawn Notes prior to the Early Tender Time. The company expects to make payments on accepted Notes by July 23, 2021. The Offer will expire on August 4, 2021, unless extended. Barclays Capital Inc. and Citigroup Global Markets Inc. are leading the transaction.

McKesson Corporation (NYSE: MCK) announced early tender results for its cash tender offer to purchase up to $500 million of various Notes. As of July 21, 2021, the company intends to increase the Tender Cap to $922,154,000, after receiving $922,154,000 of validly tendered Notes. This includes Series like 6.00% Notes due 2041 and 4.883% Notes due 2044, with acceptance expected for 100% of valid tenders submitted by the Early Tender Time. The Offer expires on August 4, 2021, unless extended.

AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) announced a proposed settlement addressing the majority of opioid lawsuits from state and local entities. The settlement, contingent on participation from states and political subdivisions, could provide up to $21 billion over 18 years. Contributions include $6.4 billion from each AmerisourceBergen and Cardinal Health, and $7.9 billion from McKesson. The settlement is seen as a step towards resolving opioid claims, with strong legal defenses maintained in pending litigation if not finalized.

AmerisourceBergen, Cardinal Health, and McKesson have agreed to pay up to $1.179 billion to settle opioid-related claims with New York and its subdivisions, including Nassau and Suffolk Counties. This settlement is part of ongoing negotiations for a broader resolution concerning claims from various states. The distributors will receive claims dismissal in exchange for the settlement amount and associated legal fees. While disputing the allegations, the companies view this as a step toward focusing resources on safe medication delivery and supporting affected communities.

McKesson Corporation (NYSE: MCK) has initiated a cash tender offer to purchase up to $500 million of its outstanding debt securities, including 6.00% Notes due 2041 and other series. The offer will expire on August 4, 2021, with an early tender deadline set for July 21, 2021. Holders of the notes must tender their securities by this date to receive an additional early tender payment of $50 per $1,000 principal. Pricing is based on U.S. Treasury yields plus additional fixed spreads. The company may extend or terminate the offer under specific conditions.

McKesson Corporation (NYSE: MCK) has agreed to sell its European operations in six countries, including France and Italy, to the PHOENIX group. The divestiture includes McKesson's German headquarters and various subsidiaries but excludes remaining operations in the UK and other Northern European countries. This strategic move aims to streamline McKesson's focus on growth outside Europe. The transaction is set to close in 2022, pending regulatory approvals. McKesson will discuss this sale further during its earnings call on August 4, 2021.

McKesson Corporation (NYSE: MCK) is set to release its first quarter fiscal 2022 financial results on August 4, 2021, after market close. A live webcast of the earnings conference call will be hosted at 4:30 PM ET, allowing investors to review the results. Interested parties can access the webcast on McKesson's Investor Relations website.

As a global leader in healthcare supply chain management and services, McKesson aims to innovate and provide effective healthcare solutions.

McKesson Corporation (NYSE:MCK) reported Q4 and FY21 results, showing FY21 revenues of $238.2 billion, a 3% increase. Q4 revenues were $59.1 billion, up 1%. Adjusted earnings per diluted share rose 15% for FY21 to $17.21. However, the company faced a significant loss of $28.26 per diluted share from continuing operations due to an $8.1 billion opioid-related liability. McKesson expects FY22 adjusted earnings per diluted share between $18.85 and $19.45, reflecting projected revenue growth of 3% to 6% and continued strong cash flow generation.

The Board of Directors of McKesson Corporation (NYSE: MCK) has declared a regular dividend of 42 cents per share of common stock. This dividend will be payable on July 1, 2021, to stockholders of record on June 1, 2021. McKesson is a leader in healthcare supply chain management and partners with various stakeholders in the healthcare sector to ensure safe and cost-effective distribution of medical products.